Combating pan-coronavirus infection by indomethacin through simultaneously inhibiting viral replication and inflammatory response DOI Creative Commons
Yining Wang, Pengfei Li, Lei Xu

et al.

iScience, Journal Year: 2023, Volume and Issue: 26(9), P. 107631 - 107631

Published: Aug. 16, 2023

Severe infections with coronaviruses are often accompanied hyperinflammation, requiring therapeutic strategies to simultaneously tackle the virus and inflammation. By screening a safe-in-human broad-spectrum antiviral agents library, we identified that indomethacin can inhibit pan-coronavirus infection in human cell airway organoids models. Combining oral drugs authorized for treating COVID-19 results synergistic anti-coronavirus activity. Coincidentally, library of FDA-approved as most potent potentiator interferon response through increasing STAT1 phosphorylation. interferon-alpha exerted effects against multiple coronaviruses. The activity is associated activating response. In co-culture system lung epithelial cells macrophages, inhibited both viral replication inflammatory Collectively, inhibitor virus-triggered potential be further augmented by combining it or interferon-alpha.

Language: Английский

Innate immunity and interferon in SARS-CoV-2 infection outcome DOI Creative Commons

Ram Savan,

Michael Gale

Immunity, Journal Year: 2023, Volume and Issue: 56(7), P. 1443 - 1450

Published: July 1, 2023

Language: Английский

Citations

25
mRNA vaccine platforms: linking infectious disease prevention and cancer immunotherapy DOI Creative Commons
Dariush Haghmorad, Majid Eslami,

Niloufar Orooji

et al.

Frontiers in Bioengineering and Biotechnology, Journal Year: 2025, Volume and Issue: 13

Published: March 12, 2025

The advent of mRNA vaccines, accelerated by the global response to COVID-19 pandemic, marks a transformative shift in vaccine technology. In this article, we discuss development, current applications, and prospects vaccines for both prevention treatment infectious diseases oncology. By leveraging capacity encode antigens within host cells directly, provide versatile scalable platform suitable addressing broad spectrum pathogens tumor-specific antigens. We highlight recent advancements design, innovative delivery mechanisms, ongoing clinical trials, with particular emphasis on their efficacy combating diseases, such as COVID-19, Zika, influenza, well emerging potential cancer immunotherapy. also address critical challenges, including stability, optimization immune responses, broader issue accessibility. Finally, review strategies advancing next-generation aim overcoming limitations technology enhancing preventive therapeutic approaches oncological diseases.

Language: Английский

Citations

1
Therapeutic Effectiveness of Interferon-α2b against COVID-19 with Community-Acquired Pneumonia: The Ukrainian Experience DOI Open Access
Oleksandr Kamyshnyi, G. D. Koval,

Olha Kobevko

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(8), P. 6887 - 6887

Published: April 7, 2023

Despite several targeted antiviral drugs against SARS-CoV-2 currently being available, the application of type I interferons (IFNs) still deserves attention as an alternative strategy. This study aimed to assess therapeutic effectiveness IFN-α in hospitalized patients with COVID-19-associated pneumonia. The prospective cohort included 130 adult coronavirus disease (COVID-19). A dose 80,000 IU IFN-α2b was administered daily intranasally for 10 days. Adding standard therapy reduces length hospital stay by 3 days (p < 0.001). level CT-diagnosed lung injuries reduced from 35% 15% = 0.011) and CT decreased 50% 0.017) discharge. In group receiving IFN-α2b, SpO2 index before after treatment increased 94 (92-96, Q1-Q3) 96 (96-98, 0.001), while percentage normal saturation (from 33.9% 74.6%, p 0.05), but low 52.5% 16.9%) very 13.6% 8.5%) categories. addition has a positive effect on course severe COVID-19.

Language: Английский

Citations

17
Metformin Therapy Changes Gut Microbiota Alpha-Diversity in COVID-19 Patients with Type 2 Diabetes: The Role of SARS-CoV-2 Variants and Antibiotic Treatment DOI Creative Commons
Pavlo Petakh, Iryna Kamyshna, Valentyn Oksenych

et al.

Pharmaceuticals, Journal Year: 2023, Volume and Issue: 16(6), P. 904 - 904

Published: June 20, 2023

The gut microbiota play a crucial role in maintaining host health and have significant impact on human disease. In this study, we investigated the alpha diversity of COVID-19 patients analyzed variants, antibiotic treatment, type 2 diabetes (T2D), metformin therapy composition diversity. We used culture-based method to analyze calculated alpha-diversity using Shannon H' Simpson 1/D indices. collected clinical data, such as length hospital stay (LoS), C-reactive protein (CRP) levels, neutrophil-to-lymphocyte ratio. found that with T2D had significantly lower than those without T2D. Antibiotic use was associated reduction alpha-diversity, while an increase. did not find differences between Delta Omicron groups. stay, CRP NLR showed weak moderate correlations Our findings suggest diverse may benefit Interventions preserve or restore diversity, avoiding unnecessary use, promoting therapy, incorporating probiotics, improve patient outcomes.

Language: Английский

Citations

17
Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study DOI Creative Commons
Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Kamyshna

et al.

Viruses, Journal Year: 2024, Volume and Issue: 16(1), P. 112 - 112

Published: Jan. 12, 2024

This study investigates the intricate interplay between Metabolic-associated Fatty Liver Disease (MAFLD) and COVID-19, exploring impact of MAFLD on disease severity, outcomes, efficacy antiviral agent Paxlovid (nirmatrelvir/ritonavir). MAFLD, affecting a quarter global population, emerges as potential risk factor for severe yet underlying pathophysiological mechanisms remain elusive. focuses clinical significance Paxlovid, first orally bioavailable granted Emergency Use Authorization in United States. Notably, outcomes from phase II/III trials exhibit an 88% relative reduction COVID-19-associated hospitalization or mortality among high-risk patients. Despite conflicting data association COVID-19 this research strives to bridge gap by evaluating effectiveness patients with addressing scarcity relevant studies.

Language: Английский

Citations

6
Genomic insight into COVID-19 severity in MAFLD patients: a single-center prospective cohort study DOI Creative Commons
Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Kamyshna

et al.

Frontiers in Genetics, Journal Year: 2024, Volume and Issue: 15

Published: Sept. 4, 2024

This study investigated the influence of single nucleotide polymorphisms (SNPs) in genes associated with interferon pathway (IFNAR2 rs2236757), antiviral response (OAS1 rs10774671, OAS3 rs10735079), and viral entry (ACE2 rs2074192) on COVID-19 severity their association nonalcoholic fatty liver disease (MAFLD). We did not observe a significant between SNPs severity. While IFNAR2 rs2236757 A allele was correlated higher creatinine levels upon admission G lower band neutrophils discharge, these findings require further investigation. The distribution OAS gene (rs10774671 rs10735079) differ MAFLD patients non-MAFLD patients. Our population's ACE2 rs2074192 genotypes alleles differed from that European reference population. Overall, our suggest specific may be major contributors to patient population, highlighting potential role other genetic factors environmental influences.

Language: Английский

Citations

6
The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence DOI Creative Commons
Mykhailo Buchynskyi, Iryna Kamyshna, Valentyn Oksenych

et al.

Viruses, Journal Year: 2023, Volume and Issue: 15(5), P. 1072 - 1072

Published: April 27, 2023

The global population is currently experiencing the impact of SARS-CoV-2 coronavirus, which has caused Coronavirus Disease 2019 (COVID-19) pandemic. With our profound comprehension COVID-19, encompassing involvement sequence respiratory tract, gastrointestinal system, and cardiovascular apparatus, multiorgan symptoms this infectious disease have been discerned. Metabolic-associated fatty liver (MAFLD), formerly known as non-alcoholic (NAFLD), a pervasive public health concern intricately linked with metabolic dysregulation estimated to afflict one-fourth adult population. burgeoning focus on association between COVID-19 MAFLD justified by potential role latter risk factor for both infection subsequent emergence severe symptoms. Investigations suggested that changes in innate adaptive immune responses among patients may play determining severity COVID-19. remarkable similarities observed cytokine pathways implicated diseases imply existence shared mechanisms governing chronic inflammatory characterizing these conditions. effect illness remains uncertain, indicated conflicting results cohort investigations.

Language: Английский

Citations

14
Genetic Predictors of Comorbid Course of COVID-19 and MAFLD: A Comprehensive Analysis DOI Creative Commons
Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Kamyshna

et al.

Viruses, Journal Year: 2023, Volume and Issue: 15(8), P. 1724 - 1724

Published: Aug. 12, 2023

Metabolic-associated fatty liver disease (MAFLD) and its potential impact on the severity of COVID-19 have gained significant attention during pandemic. This review aimed to explore genetic determinants associated with MAFLD, previously recognized as non-alcoholic (NAFLD), their influence outcomes. Various polymorphisms, including PNPLA3 (rs738409), GCKR (rs780094), TM6SF2 (rs58542926), LYPLAL1 (rs12137855), been investigated in relation MAFLD susceptibility progression. Genome-wide association studies meta-analyses revealed associations between these variants risk, well effects lipid metabolism, glucose regulation, function. Furthermore, emerging evidence suggests a possible connection MAFLD-associated polymorphisms COVID-19. Studies exploring indicated outcomes shown conflicting results. Some observed protective effect certain against severe COVID-19, while others reported no associations. highlights importance understanding implications for Further research is needed elucidate precise mechanisms linking develop gene profiling tools early prediction If confirmed severity, could aid identification high-risk individuals improving management

Language: Английский

Citations

13
Modulatory Roles of AHR, FFAR2, FXR, and TGR5 Gene Expression in Metabolic-Associated Fatty Liver Disease and COVID-19 Outcomes DOI Creative Commons
Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Kamyshna

et al.

Viruses, Journal Year: 2024, Volume and Issue: 16(6), P. 985 - 985

Published: June 19, 2024

Metabolic-associated fatty liver disease (MAFLD) is a risk factor for severe COVID-19. This study explores the potential influence of gut hormone receptor and immune response gene expression on COVID-19 outcomes in MAFLD patients.

Language: Английский

Citations

5
Recent advances in the management of knee osteoarthritis: a narrative review DOI Creative Commons
Viktor Shtroblia, Pavlo Petakh, Iryna Kamyshna

et al.

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: Jan. 21, 2025

Knee osteoarthritis (OA) is a common condition that causes pain and reduces the quality of life for many people. It also leads to high health financial costs. Managing knee OA requires using different methods together best results. This review overviews current therapeutic options pain, focusing on their efficacy, safety, potential roles in clinical practice. Topical treatments, such as NSAIDs capsaicin, offer significant relief with minimal systemic side effects are suitable initial therapy, nonpharmacologic interventions like exercise and, when relevant, weight loss. Oral analgesics, including acetaminophen opioids, have limited efficacy serious effects, making them appropriate only short-term or rescue therapy. Intra-articular injections, corticosteroids, hyaluronic acid, platelet rich plasma, demonstrate varying levels safety. Nutritional supplements, curcumin, Boswellia serrata , glucosaminechondroitin combinations, modest benefits used adjuncts standart treatment. Nonpharmacological transcutaneous electrical nerve stimulation (TENS), acupuncture, local heat provide variable should be customized based individual patient responses. Targeted biologic agents, antibodies TNF-α, IL-1, NGF, hold promise more precise relief; however, further research required establish routine use. Treating personalized, combining several methods. Research must continue improve treatments make safer.

Language: Английский

Citations

0